Formiga, FrancescChivite, DavidNuñez, JulioMoreno Garcia, Ma CarmenManzano, LuisArevalo-Lorido, Jose CarlosCerqueiro, Jose ManuelGarcia Campos, AlvaroTrullas, Joan CarlesMontero-Perez-Barquero, Manuel2023-05-032023-05-032022-06-02Formiga F, Chivite D, Nuñez J, Moreno García MC, Manzano L, Arévalo-Lorido JC, et al. Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. Rev Port Cardiol. 2022 Oct;41(10):853-861. English, Portuguesehttp://hdl.handle.net/10668/22497Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/All-cause mortalityBeta-adrenergic receptor blockersBloqueadores dos recetores β-adrenérgicosFração de ejeção preservadaHeart failureHeart failure readmissionInsuficiência cardíacaMortalidade globalPreserved ejection fractionReinternamento por insuficiência cardíacaAdrenergic beta-antagonistsAngiotensin receptor antagonistsAngiotensin-converting enzyme inhibitorsAngiotensinsHeart failureHumansNeprilysinReceptors, adrenergic, betaSodium potassium chloride symporter inhibitorsStroke volumeResearch article36207068open accessAngiotensinasAntagonistas adrenérgicos betaAntagonistas de receptores de angiotensinaInhibidores de la enzima convertidora de angiotensinaInhibidores del simportador de cloruroInsuficiencia CardíacaNeprilisina10.1016/j.repc.2021.06.0272174-2030https://doi.org/10.1016/j.repc.2021.06.027